Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_00541 |
| Species: | Homo sapiens |
| Position : | chr2:74399364-74399764 |
| Year: | 2022 |
| Title: | Discovery and Functional Characterization of Two Regulatory Variants Underlying Lupus Susceptibility at 2p131 |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | hepatocellular carcinoma |
| PMID: | 35741778 |
| MONDO: | MONDO:0007256 |
| Tissue: | Liver |
| Tissue Ontology ID: | UBERON:0002107 |
| Cell Source: | HepG2 |
| CVCL ID: | CVCL_0027 |
| Cell Type: | hepatocellular carcinoma cell |
| Cell Ontology ID: | CL:0000182 |
| Experiment Type: | Enhancer activity assay, TF binding assay |
| High Throughput Method: | ChIP-seq, RNA-seq |
| Low Throughput Method: | Luciferase Reporter Assay, ChIP-RT-qPCR, qRT-PCR, Western blot |
| Target gene : | DGUOK |
| TF name : | ARID3A |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| ARID3A | Direct p53 effectors | pid | 141 |
| ARID3A | TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | reactome | 13 |